Search Results - "ExteNET Study Group"

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

Authors: Chan A Moy B Mansi J et al.

Corporate Authors: Chan A Moy B Mansi J et al.

Source: Clinical breast cancer [Clin Breast Cancer] 2021 Feb; Vol. 21 (1), pp. 80-91.e7. Date of Electronic Publication: 2020 Oct 06.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Holmes FA Moy B Delaloge S et al.

Corporate Authors: Holmes FA Moy B Delaloge S et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 May; Vol. 184, pp. 48-59. Date of Electronic Publication: 2023 Feb 10.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Martin M Holmes FA Ejlertsen B et al.

Corporate Authors: Martin M Holmes FA Ejlertsen B et al.

Source: The Lancet. Oncology [Lancet Oncol] 2017 Dec; Vol. 18 (12), pp. 1688-1700. Date of Electronic Publication: 2017 Nov 13.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Chan A Delaloge S Holmes FA et al.

Corporate Authors: Chan A Delaloge S Holmes FA et al.

Source: The Lancet. Oncology [Lancet Oncol] 2016 Mar; Vol. 17 (3), pp. 367-377. Date of Electronic Publication: 2016 Feb 10.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Indian Society of Medical and Paediatric Oncology (ISMPO)—Breast Cancer in Young Guidelines.

Authors: Bajpai, Jyoti Gandhi, Shruti Sanjay Rajappa, Senthil et al.

Source: Indian Journal of Medical & Paediatric Oncology. Apr2025, Vol. 46 Issue 2, p119-133. 15p.

Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs.

Authors: Guy, Michael Teixeira, Andre Shrier, Allison et al.

Source: PLoS ONE. 1/24/2024, Vol. 19 Issue 1, p1-16. 16p.

Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer.

Authors: Viganò, Mauro La Milia, Marta Grassini, Maria Vittoria et al.

Source: Cancers. Mar2023, Vol. 15 Issue 6, p1766. 34p.

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.

Authors: Jerusalem G Lancellotti P Kim SB

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2019 Sep; Vol. 177 (2), pp. 237-250. Date of Electronic Publication: 2019 Jun 05.

Publication Type: Journal Article; Review

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Considerations for hormone therapy use in survivors of breast cancer.

Authors: Pederson HJ; Cleveland Clinic, Cleveland, Ohio.

Source: Menopause (New York, N.Y.) [Menopause] 2025 Nov 01; Vol. 32 (11), pp. 1060-1062. Date of Electronic Publication: 2025 Nov 01.

Publication Type: Journal Article

Journal Info: Publisher: Lippincott-Raven Publishers Country of Publication: United States NLM ID: 9433353 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-0374 (Electronic) Linking ISSN: 10723714 NLM ISO Abbreviation: Menopause Subsets: MEDLINE

Current Treatment Approaches for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Adjuvant and Neoadjuvant Settings.

Authors: Goyal, Pankaj Doval, Dinesh Chandra Agarwal, Chaturbhuj et al.

Source: Indian Journal of Medical & Paediatric Oncology. 2021, Vol. 42 Issue 1, p35-45. 11p.

Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.

Authors: Escudero-Vilaplana V Collado-Borrell R Del Monte-Millán M et al.

Source: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2021 Aug; Vol. 29 (8), pp. 4673-4681. Date of Electronic Publication: 2021 Jan 28.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE

The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.

Authors: Patel, Aena Unni, Nisha Peng, Yan

Source: Cancers. Aug2020, Vol. 12 Issue 8, p2081-2081. 1p.

NMR-Based Metabolomics to Evaluate Individual Response to Treatments.

Authors: Vignoli A Meoni G Ghini V et al.

Source: Handbook of experimental pharmacology [Handb Exp Pharmacol] 2023; Vol. 277, pp. 209-245.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902231 Publication Model: Print Cited Medium: Print ISSN: 0171-2004 (Print) Linking ISSN: 01712004 NLM ISO Abbreviation: Handb Exp Pharmacol Subsets: MEDLINE

Forward and reverse cardio-oncology.

Authors: Meijers WC Aboumsallem JP Lyon AR et al.

Source: Physiological reviews [Physiol Rev] 2026 Jan 01; Vol. 106 (1), pp. 587-644. Date of Electronic Publication: 2025 Sep 22.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Physiological Society Country of Publication: United States NLM ID: 0231714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1210 (Electronic) Linking ISSN: 00319333 NLM ISO Abbreviation: Physiol Rev Subsets: MEDLINE

Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.

Authors: Ma S Zhou Y Ma D et al.

Source: American journal of cancer research [Am J Cancer Res] 2024 Sep 15; Vol. 14 (9), pp. 4218-4235. Date of Electronic Publication: 2024 Sep 15 (Print Publication: 2024).

Publication Type: Journal Article; Review

Journal Info: Publisher: e-Century Pub. Corp Country of Publication: United States NLM ID: 101549944 Publication Model: eCollection Cited Medium: Print ISSN: 2156-6976 (Print) Linking ISSN: 21566976 NLM ISO Abbreviation: Am J Cancer Res Subsets: PubMed not MEDLINE

From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas.

Authors: Guo S Zheng X Chen W et al.

Source: Neuro-oncology advances [Neurooncol Adv] 2024 Jun 24; Vol. 6 (1), pp. vdae107. Date of Electronic Publication: 2024 Jun 24 (Print Publication: 2024).

Publication Type: Journal Article; Review

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE

Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments.

Authors: Soltani M Sokoloff LJ Fradley MG

Source: Current oncology reports [Curr Oncol Rep] 2023 Aug; Vol. 25 (8), pp. 923-935. Date of Electronic Publication: 2023 May 30.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE

Research Status of Systemic Adjuvant Therapy for Early Breast Cancer.

Authors: Hu W Xu D Li N

Source: Cancer control : journal of the Moffitt Cancer Center [Cancer Control] 2023 Jan-Dec; Vol. 30, pp. 10732748231209193.

Publication Type: Journal Article; Review

Journal Info: Publisher: SAGE Publishing Country of Publication: United States NLM ID: 9438457 Publication Model: Print Cited Medium: Internet ISSN: 1526-2359 (Electronic) Linking ISSN: 10732748 NLM ISO Abbreviation: Cancer Control Subsets: MEDLINE

Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach.

Authors: Balogun TA Iqbal MN Saibu OA et al.

Source: Journal of biomolecular structure & dynamics [J Biomol Struct Dyn] 2022; Vol. 40 (23), pp. 12772-12784. Date of Electronic Publication: 2021 Sep 13.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 8404176 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-0254 (Electronic) Linking ISSN: 07391102 NLM ISO Abbreviation: J Biomol Struct Dyn Subsets: MEDLINE

Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018.

Authors: Fu M Naci H Booth CM et al.

Source: JAMA internal medicine [JAMA Intern Med] 2021 Dec 01; Vol. 181 (12), pp. 1596-1604.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589534 Publication Model: Print Cited Medium: Internet ISSN: 2168-6114 (Electronic) Linking ISSN: 21686106 NLM ISO Abbreviation: JAMA Intern Med Subsets: MEDLINE